Another new PMSA-linked radioisotope enters clinical trials in prostate cancer

[Paul Edwards]

"Another new form of radioisotope, copper-64 (⁶⁴Cu), has recently undergone Phase I clinical testing for similar uses when linked to the PSMA-617 ligand.  One of the potential benefits of a ⁶⁴Cu-PSMA imaging agent is that it is more stable and has a longer half-life than ⁶⁸Ga.  This means that this imaging agent could be made at a central facility and distributed from there to clinical PET scan centers that don’t have the radiochemistry capabilities necessary for the preparation of ⁶⁸Ga-PSMA imaging agents."

 

The New Prostate Cancer Infolink has a report on the trial carried out at two nuclear medicine centers (in Vienna, Austria, and Bad Berka, Germany).